The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831

The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831

  • World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class
  • The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class
  • The NOX inhibitor therapeutic class has significant potential in fibrotic, inflammatory, neurodegenerative, and oncology disorders

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, today announced that the World Health Organization (WHO) has recommended setanaxib as the international nonproprietary name (INN) for GKT831.

For more information, https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2019/2019-07-22-GKTX_WHO_Approves_NOX_SETANAXIB_EN_70866.pdf